Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Inflamasi memegang peranan penting dalam IMA-EST, terutama kejadia cedera reperfusi. Kolkisin merupakan sediaan obat anti inflamasi, yang dapat menekan inflamasi saat terjadi cedera reperfusi. Kami menilai keefektivan dari pemberian kolkisin pada pasien IMA-EST yang menjalani IKPP dalam menekan cedera reperfusi. Metode: Penelitian ini merupakan uji klinis, tersamar ganda, dengan plasebo, yang dilakukan multisenter di dua rumah sakit di Jakarta dengan fasilitas IKPP dari Desember 2022 hingga April 2023. Pasien IMA-EST yan menjalani IKPP diberikan dosis muat kolkisin 2 mg, kemudian dosis pemeliharaan 2x0,5 mg selama 2 hari, dan amilum pada kelompok plasebo. Pasien diamati kejadian cedera reperfusi berupa TIMI flow, kejadian aritmai, syok dan aritmia akibat reperfusi.Hasil: Sebanyak 77 subyek IMA-EST dengan rerata usia 55.2 ± 9.9 tahun menjalani IKPP. 37 subyek mendapat kolkisin, 40 subyek mendapat placebo. Kebanyakan subjek ialah laki-laki (77.5%), menderita 3 vessel disease (44,1%), oklusi di LAD ( 53,2%). Pemberian kolkisin tidak berhasil menurunkan kejadia cedera iskemia reperfusi (51.5% vs. 42.4%; p = 0.437). Analisi komorbiditas ( hipertensi, gagal ginjal, diabetes mellitus, dan obesitas) dan hasil angiografi ( jumlah pembuluh darah coroner yang sakit, diameter pembuluh darah, dan lokasi penyumbatan yang menyebabkan IMA-EST) tidak berhasil menunjukkan kemaknaan secara statistic. Kejadian efek samping sama pada kedua kelompok (21.6% vs. 15%). Kesimpulan: Pemberian kolkisin pada pasien IMA-EST yang menjalani IKPP tidak berhasil menurunkan kejadian cedera reperfusi.

---

Background: Inflammation plays a role in ST-segment elevation myocardial infarction (STEMI), especially in reperfusion injury (RI). Colchicine, an anti-inflammatory drug, can suppress inflammation during RI. We assessed the effectiveness of administering colchicine to STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in suppressing RI events.

Methods: This study was a randomized, double-blind, placebo-controlled clinical trial conducted in a multicenter manner at two hospitals in Jakarta with IKPP facilities from December 2022 to April 2023. STEMI patients that underwent PPCI received 2 g of colchicine as a loading dose and a maintenance dose of 0.5 g every 12 hours for two days or amylum at a similar dose. Patients were observed for RI events (low-flow thrombolysis in myocardial infarction (0–2) during angiography procedure, reperfusion arrhythmia, cardiogenic shock, or persistent chest pain).

Results: Seventy-seven STEMI patients with a mean age of 55.2 ± 9.9 years underwent PPCI. Of these patients, 37 received colchicine, and 40 received a placebo. Most subjects were male (77.5%), suffered three-vessel disease (44.15%), and occlusion in left anterior descending coronary artery (53.24%). Colchicine was found to fail to reduce the incidence of ischemia-RI (51.5% vs. 42.4%; p = 0.437). Analysis of comorbidities (hypertension, chronic kidney disease, diabetes mellitus, and obesity) and angiography results (vessel disease, lesion diameter, and culprit artery) failed to demonstrate a statistical difference in RI. Side effects were similar in the colchicine and placebo groups (21.6% vs. 15%).

Conclusion: Colchicine administration in STEMI patients undergoing PPCI failed to reduce RI.

"

"Latar Belakang: Human immuno deficiency virus/ Acquired Immune Deficiency Syndrome HIV/AIDS merupakan masalah global yang menunjukkan adanya keterkaitan antara kasus HIV/AIDS dengan adanya kejadian aterosklerosis sebagai pemicu terjadinya kasus Penyakit Jantung Koroner PJK . Pemberian Antiretroviral ARV tersebut juga berisiko untuk kejadian PJK melalui mekanisme dislipidemia, lipodistrofi, resistensi insulin dan gangguan hati, yang juga bisa menyebabkan penebalan tunika intima media.Tujuan: Mendapatkan korelasi perubahan kadar CD 4, kadar viral load dan Indeks Massa Tubuh terhadap perubahan ketebalan tunika intima media arteri karotis pada pasien HIV yang mendapat ARV lini pertama selama 12 bulanMetode: Penelitian ini merupakan studi uji korelasi terhadap 54 pasien HIV yang menggunakan data sekunder penelitian JACCANDO PROJECT. Data yang digunakan adalah data USG doppler arteri karotis, hasil CD 4, hasil viral load dan hasil Indeks Massa Tubuh IMT .Hasil: Median CD 4 sebelum pemberian ARV ialah 68 sel/ l, sedangkan median CD 4 sesudah pemberian ARV 286,5 sel/ l. Median kadar viral load sebelum ARV sebesar 1.79 log10 copy/ml, sedangkan median viral load sesudah ARV yaitu 0 log10 copy/ml. Median IMT sebelum ARV 19.6, sedangkan median sesudah 12 bulan ARV 19.72. Rerata tunika intima media arteri karotis kiri sebelum dan sesudah pemberian ARV selama 12 bulan ialah 0.58 dan 0.63 dengan p-value 0.031. Korelasi perubahan kadar CD 4 dengan ketebalan tunika intima media arteri karotis kanan r= 0.08, p=0,58 , dan kiri r= 0.01, p=0,965 . Korelasi perubahan kadar viral load dengan ketebalan tunika intima media arteri karotis kanan r= 0.09, p=0,54 dan arteri karotis kiri r= 0.06, p=0,66 . Korelasi perubahan kadar IMT dengan perubahan ketebalan tunika intima kanan r= - 0.11, p=0,37 dan kiri r= -0.18, p=0,19 .Simpulan: Ketebalan tunika intima mengalami peningkatan antara sebelum dan sesudah pengobatan antiretroviral, namun tidak didapatkan korelasi antara kadar CD4, Viral load dan indeks massa tubuh dengan ketebalan tunika intima arteri karotis.

---

Background Human immuno deficiency virus Acquired Immune Deficiency Syndrome HIV AIDS is currently a global issue related with coronary artery disease. The effects of antiretroviral ARV is accompanied with some negative features such as dyslipidemia, lipodystrophy, insulin resistance and liver dysfunction which all contribute to increasing tunima intima thickness.Objective To acquire correlation between level of CD4, viral load, and Body Mass Index BMI with changes in tunica intima of carotid artery thickness in HIV patients receiving first line ARV for 12 monthsMethods This study is a correlation study involving 54 HIV patients using secondary data from the JACCANDO PROJECT research data such as Doppler ultrasound of the carotid artery, CD4 values, viral load as well as BMI.Results Median CD before antiretroviral treatment was 68 cells l, median CD 4 after ARV 286.5 cell l. The median viral load rate before ARV was 1.79 log10 copy ml, while median viral load after ARV was 0 log10 copy ml. The median BMI before ARV was 19.6, while median after 12 months of ARV was 19.72. The mean of the left artery carotid artery intima media before and after ARV administration for 12 months was 0.58 and 0.63 with p value 0.031. Correlation of changes in CD4 levels with the thickness of tunica intima medium of right carotid artery r 0.08, p 0,58 , and left r 0.01, p 0,965 . Correlation of changes in viral load levels with the tunica thickness of the right carotid artery medium r 0.09, p 0,54 and left carotid artery r 0.06, p 0.66 . Correlation of changes in BMI levels with changes in thickness of the right tunica intima r 0.11, p 0.37 and left carotid artery r 0.18, p 0.19 .Conclusion The thickness of intima tunica increased after antiretroviral treatment, but no correlation found between CD4, viral load and BMI level with the thickness of the intima tunica carotid artery."